Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 82.7 Cr.
- Current Price ₹ 65.8
- High / Low ₹ 105 / 58.1
- Stock P/E 16.8
- Book Value ₹ 39.7
- Dividend Yield 0.00 %
- ROCE 20.3 %
- ROE 14.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 7.46 | 7.99 | 30.10 | 32.35 | |
| 4.22 | 4.59 | 21.09 | 22.58 | |
| Operating Profit | 3.24 | 3.40 | 9.01 | 9.77 |
| OPM % | 43.43% | 42.55% | 29.93% | 30.20% |
| 0.00 | 0.35 | 0.57 | 0.69 | |
| Interest | 0.02 | 0.08 | 0.23 | 0.20 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| Profit before tax | 2.27 | 2.69 | 6.86 | 7.01 |
| Tax % | 22.91% | 0.00% | 31.63% | 30.39% |
| 1.76 | 2.69 | 4.69 | 4.88 | |
| EPS in Rs | 204.56 | 5.57 | 3.91 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 41% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.13 | 8.42 | 12.57 | |
| Reserves | 12.05 | 8.41 | 37.35 | |
| 1.87 | 1.67 | 3.67 | ||
| 1.79 | 2.75 | 6.66 | ||
| Total Liabilities | 15.84 | 21.25 | 60.25 | |
| 11.78 | 9.62 | 19.20 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 4.33 | 6.20 | |
| 4.06 | 7.30 | 34.85 | ||
| Total Assets | 15.84 | 21.25 | 60.25 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 4.21 | 6.47 | 2.93 | ||
| -10.01 | -5.23 | -13.67 | ||
| 7.14 | -0.42 | 30.79 | ||
| Net Cash Flow | 1.34 | 0.83 | 20.05 | |
| Free Cash Flow | -8.56 | 6.15 | -9.93 | |
| CFO/OP | 124% | 72% | 40% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 37.46 | 17.70 | 6.43 | |
| Inventory Days | 296.56 | 83.33 | 78.88 | |
| Days Payable | 1,102.60 | 70.00 | 254.03 | |
| Cash Conversion Cycle | -768.58 | 31.04 | -168.72 | |
| Working Capital Days | 5.94 | 21.58 | 55.74 | |
| ROCE % | 46.45% | 20.28% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Average Revenue per Test (ARPT) INR ・Includes some standalone data |
|
||
| Number of Institutional Clients Number ・Standalone data |
|||
| Pathology Tests Performed Number ・Includes some standalone data |
|||
| Radiology Tests Performed Number ・Includes some standalone data |
|||
| Total Diagnostic Centres Number ・Standalone data |
|||
| Total Patients Served Number ・Includes some standalone data |
|||
| Total Tests Performed Number ・Includes some standalone data |
|||
| Average Revenue per Patient INR |
|||
Extracted by Screener AI
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
29 May 2026 - Invicta Diagnostic reported no deviation in IPO fund use for half year and year ended March 31, 2026.
-
Updates
25 May 2026 - Board approved FY26 audited standalone and consolidated results on May 18, 2026; auditors issued unmodified opinion.
-
Analysts/Institutional Investor Meet/Con. Call Updates
25 May 2026 - H2 FY26 conference call transcript; FY26 income ₹33.04 crore, PAT ₹4.87 crore, expansion updates.
-
Analysts/Institutional Investor Meet/Con. Call Updates
23 May 2026 - Audio recording of 23 May 2026 earnings call for half-year ended 31 March 2026 uploaded online.
-
Analysts/Institutional Investor Meet/Con. Call Updates
22 May 2026 - Investor presentation for earnings call on 23 May 2026 on half-year results ended 31 March 2026.
Concalls
-
May 2026Transcript PPT
Business Profile[1]
PC Diagnostics (Invicta) is a diagnostic chain in the Mumbai Metropolitan Region (MMR) offering radiology and pathology services. The company operates 7 diagnostic centres + 1 centralised laboratory, built on a hub-and-spoke model.